Completed PHASE1 INTERVENTIONAL 4-arm NCT02045953

A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer

A Randomised, Open-Label, Four Period, Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate From FLIXOTIDE™ 250 HFA pMDI and of Fluticasone Propionate and Salmeterol From SERETIDE™ 250/25 HFA pMDI When Given With the VENTOLIN Mini-Spacer Compared to the Aerochamber Plus Spacer in Healthy Subjects

Sponsor: GlaxoSmithKline

Conditions Asthma

Interventions Aerochamber Plus spacer VENTOLIN Mini-Spacer

Updated 7 times since 2017 Last updated: Jun 18, 2018 Started: Jan 29, 2014 Primary completion: Mar 13, 2014 Completion: Mar 13, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Asthma, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jul 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jul 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Jul 2017 [monthly]

Completed PHASE1

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom